-transparent.png){kind=logo}
Fifteen patients with advanced epithelial ovarian cancer were treated with 4-demethoxydaunorubicin (IMI-30) after platinum failure. A total of 33 courses of IMI-30 15 mg/m2, per os, daily for 3 consecutive days every 3 weeks were performed. Three patients experienced severe hematologic toxicity (WHO grade greater than or equal to 3), while gastroenteric toxicity was acceptable and no cardiotoxicity was observed. One minor response, 4 stabilization of disease and 7 progression were observed in 12 evaluable patients. In conclusion, IMI-30, at this scheduling, is inactive in our small series of heavily pretreated epithelial ovarian cancer patients.
Related Publications
M Bruzzone, and
S Chiara, and
A Falcone, and
G Graziani, and
P F Conte, and
R Rosso
May 1986,
Gynecologic oncology,
M Bruzzone, and
S Chiara, and
A Falcone, and
G Graziani, and
P F Conte, and
R Rosso
January 1985,
Giornale italiano di chemioterapia,
M Bruzzone, and
S Chiara, and
A Falcone, and
G Graziani, and
P F Conte, and
R Rosso
April 1985,
Cancer,
M Bruzzone, and
S Chiara, and
A Falcone, and
G Graziani, and
P F Conte, and
R Rosso
March 1987,
British journal of clinical pharmacology,
M Bruzzone, and
S Chiara, and
A Falcone, and
G Graziani, and
P F Conte, and
R Rosso
May 1985,
Cancer treatment reports,
M Bruzzone, and
S Chiara, and
A Falcone, and
G Graziani, and
P F Conte, and
R Rosso
January 1984,
Haematologica,
M Bruzzone, and
S Chiara, and
A Falcone, and
G Graziani, and
P F Conte, and
R Rosso
April 1989,
Seminars in oncology,
M Bruzzone, and
S Chiara, and
A Falcone, and
G Graziani, and
P F Conte, and
R Rosso
January 1987,
Haematology and blood transfusion,
M Bruzzone, and
S Chiara, and
A Falcone, and
G Graziani, and
P F Conte, and
R Rosso
January 1985,
Drugs under experimental and clinical research,
M Bruzzone, and
S Chiara, and
A Falcone, and
G Graziani, and
P F Conte, and
R Rosso
January 2004,
Oncology,
